This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Okamoto, H.
Right arrow Articles by Yamaguchi, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Okamoto, H.
Right arrow Articles by Yamaguchi, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, November 2001, p. 3250-3252, Vol. 45, No. 11
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.11.3250-3252.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vivo Efficacy of Telithromycin (HMR3647) against Streptococcus pneumoniae and Haemophilus influenzae

Hiroki Okamoto,* Shuichi Miyazaki, Kazuhiro Tateda, Yoshikazu Ishii, and Keizo Yamaguchi

Department of Microbiology, Toho University School of Medicine, Omori-Nishi, Ota-ku, Tokyo, Japan

Received 19 March 2001/Returned for modification 3 May 2001/Accepted 3 August 2001

The in vivo activity of telithromycin against erythromycin A- and penicillin G-resistant Streptococcus pneumoniae was superior to that of azithromycin, clarithromycin, cefdinir, and levofloxacin. In respiratory tract infections caused by erythromycin A-susceptible S. pneumoniae or Haemophilus influenzae in mice, telithromycin was more effective than clarithromycin and comparable to azithromycin.

* Corresponding author. Present address: Aventis Pharma Ltd. Laboratory of Pharmacology, 1-3-2 Minamidai, Kawagoe, Saitama 350-1165, Japan. Phone: 81-49-243-2421. Fax: 81-49-243-4002. E-mail: hiroki.okamoto{at}aventis.com

Antimicrobial Agents and Chemotherapy, November 2001, p. 3250-3252, Vol. 45, No. 11
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.11.3250-3252.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Tessier, P. R., Mattoes, H. M., Dandekar, P. K., Nightingale, C. H., Nicolau, D. P. (2005). Pharmacodynamic Profile of Telithromycin against Macrolide- and Fluoroquinolone-Resistant Streptococcus pneumoniae in a Neutropenic Mouse Thigh Model. Antimicrob. Agents Chemother. 49: 188-194 [Abstract] [Full Text]  
  • Reinert, R. R. (2004). Clinical efficacy of ketolides in the treatment of respiratory tract infections. J Antimicrob Chemother 53: 918-927 [Abstract] [Full Text]  
  • Berisio, R., Harms, J., Schluenzen, F., Zarivach, R., Hansen, H. A. S., Fucini, P., Yonath, A. (2003). Structural Insight into the Antibiotic Action of Telithromycin against Resistant Mutants. J. Bacteriol. 185: 4276-4279 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»